have been evolutionarily selected to bind to biological
macromolecules and, thus, represent “privileged structures”,
129 which are excellent templates for the synthesis of
novel, biologically active, natural product-like molecules. Of
course, suitable biological assays for evaluation of the
structure-activity relationships (SARs) of the optimization
products are required for all these approaches, and thus, a
truly multidisciplinary, collaborative approach is required for
effective naturalproduct-baseddrugdiscoveryanddevelopment.